| Theravance Biopharma to Participate in an Upcoming Investor Conference |
DUBLIN , May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference. |
prnewswire.com |
2025-05-13 10:00:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript |
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial officer Aine Miller - Head-Development Conference Call Participants Marc Frahm - TD Cowen Operator Hello, ladies and gentlemen. Good afternoon. |
seekingalpha.com |
2025-05-10 20:35:16 |
Czytaj oryginał (ang.) |
| Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y |
TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year. |
zacks.com |
2025-05-09 17:40:42 |
Czytaj oryginał (ang.) |
| Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress |
DUBLIN , May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts. A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA) in the REDWOOD 0170 study (NCT03829657), an international phase 3, placebo-controlled, double-blind, randomized withdrawal trial, designed to demonstrate clinical worsening in those assigned to placebo. |
prnewswire.com |
2025-05-09 16:00:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates |
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago. |
zacks.com |
2025-05-08 23:10:43 |
Czytaj oryginał (ang.) |
| Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update |
YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 2024 1 TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 2024 2 CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled by late summer Quarter-end cash balance of $131 million, with no debt Reaffirming all financial guidance metrics DUBLIN , May 8, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2025. "As we begin the year, we remain focused on delivering against our operational priorities for YUPELRI and ampreloxetine," said Rick E Winningham, CEO of Theravance Biopharma. |
prnewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress |
DUBLIN , April 28, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts. These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). |
prnewswire.com |
2025-04-28 10:00:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 |
DUBLIN , April 24, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day. |
prnewswire.com |
2025-04-24 10:00:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting |
Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease DUBLIN , April 7, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). Both analyses were presented as platform presentations at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. |
prnewswire.com |
2025-04-07 19:55:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Participate in an Upcoming Investor Conference |
DUBLIN , March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. |
prnewswire.com |
2025-03-31 10:00:00 |
Czytaj oryginał (ang.) |
| Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report? |
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-03-28 14:35:34 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology |
DUBLIN , March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRESS Study 197) addressing nOH in patients with multiple system atrophy, which is currently ongoing. |
prnewswire.com |
2025-03-27 08:00:00 |
Czytaj oryginał (ang.) |
| Theravance's Q4 Loss In Line With Estimates, Sales Beat |
TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher. |
zacks.com |
2025-02-27 11:45:34 |
Czytaj oryginał (ang.) |
| Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript |
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Aziz Sawaf – Chief Financial officer Aine Miller – Head-Development Conference Call Participants Douglas Tsao – H.C. Wainwright Julian Harrison – BTIG David Risinger – Leerink Partners Operator Ladies and gentlemen, good afternoon. |
seekingalpha.com |
2025-02-26 22:58:09 |
Czytaj oryginał (ang.) |
| Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates |
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.03 per share a year ago. |
zacks.com |
2025-02-26 20:16:09 |
Czytaj oryginał (ang.) |
| Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results |
YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 2023 1 FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma 2 , 3 CYPRESS study on track to enroll final patient in the open label portion by mid-2025 Ended Q4 2024 with $88 million in cash, excluding the $50 million TRELEGY milestone, with cash receipt in February 2025 DUBLIN , Feb. 26, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter and full-year ended December 31, 2024. "Theravance Biopharma ended 2024 on a high note, having collaborated closely with Viatris to deliver record fourth quarter YUPELRI net sales and profitability, while achieving $50 million in TRELEGY related sales milestones," said Rick E Winningham, Theravance Biopharma CEO. |
prnewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Participate in an Upcoming Investor Conference |
DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. |
prnewswire.com |
2025-02-20 08:00:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 |
DUBLIN, Ireland , Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth quarter and full year 2024 financial results and provide a business update after market close on Wednesday, February 26, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. |
prnewswire.com |
2025-02-12 08:00:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Participate in an Upcoming Investor Conference |
DUBLIN , Feb. 5, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT). Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. |
prnewswire.com |
2025-02-05 08:00:00 |
Czytaj oryginał (ang.) |
| Theravance Bio (TBPH) Soars 8.3%: Is Further Upside Left in the Stock? |
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-01-27 07:01:13 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference |
DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team will hold investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA. |
prnewswire.com |
2024-12-17 08:00:00 |
Czytaj oryginał (ang.) |
| Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue? |
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:15 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Participate in an Upcoming Investor Conference |
DUBLIN , Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. |
prnewswire.com |
2024-11-20 08:00:00 |
Czytaj oryginał (ang.) |
| Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y |
TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance. |
zacks.com |
2024-11-13 14:30:25 |
Czytaj oryginał (ang.) |
| Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript |
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Aine Miller - Head, Development Conference Call Participants Julian Harrison - BTIG Ernie Rodriguez - TD Cowen Douglas Tsao - H.C. Wainwright Operator Ladies and gentlemen, good afternoon. |
seekingalpha.com |
2024-11-13 00:46:24 |
Czytaj oryginał (ang.) |
| Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates |
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.01 per share a year ago. |
zacks.com |
2024-11-12 21:10:23 |
Czytaj oryginał (ang.) |
| Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value |
Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241 CYPRESS enrollment in-line with expectations, with timelines on track TRELEGY net sales increased 17%, to $789 million, as reported by GSK: Q4 sales of at least ~$260 million needed to earn $25 million milestone2 Q4 sales of at least ~$610 million needed to earn $50 million milestone2 Board of Directors announces initiatives to unlock shareholder value and enhance corporate governance DUBLIN , Nov. 12, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 and announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value. Reflecting on the quarter's operational performance, Rick Winningham, Theravance Biopharma CEO commented, "Through our collaboration with Viatris, we achieved a strong quarter for YUPELRI demand and made progress on recent mix-related pricing headwinds, therein driving quarterly net sales to an all-time high. |
prnewswire.com |
2024-11-12 18:05:00 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts? |
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week. |
zacks.com |
2024-11-11 13:50:15 |
Czytaj oryginał (ang.) |
| Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance |
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article. |
zacks.com |
2024-11-11 10:51:11 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Trump Gets Re-Elected |
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio. |
zacks.com |
2024-11-08 10:21:31 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024 |
DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day. |
prnewswire.com |
2024-10-24 10:00:00 |
Czytaj oryginał (ang.) |
| Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease |
DUBLIN , Oct. 18, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, randomized, registrational revefenacin Phase 3 trials (Trials 0126 [NCT02459080] and 0127 [NCT02512510]) for YUPELRI, the first and only FDA approved once-daily nebulized long-acting muscarinic antagonist (LAMA), evaluating the area under the curve (AUC) lung function effects in moderate-to-very-severe chronic obstructive pulmonary disease (COPD) patients. These data and analyses, published in the International Journal of Chronic Obstructive Pulmonary Disease, reinforce that YUPELRI provides consistent and durable improvements in lung function, as compared with placebo, over a full 24-hours. |
prnewswire.com |
2024-10-18 13:00:00 |
Czytaj oryginał (ang.) |
| Invest Alongside Wall Street Legend Seth Klarman: 2 New Stocks He Bought and 1 He Dumped |
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management. |
247wallst.com |
2024-09-29 15:32:12 |
Czytaj oryginał (ang.) |
| Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue? |
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-04 16:35:31 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Participate in an Upcoming Investor Conference |
DUBLIN , Aug. 27, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference in New York City on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST) and will be hosting in-person meetings with the investment community at the conference. |
prnewswire.com |
2024-08-27 10:00:00 |
Czytaj oryginał (ang.) |
| Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y |
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance. |
zacks.com |
2024-08-06 16:01:30 |
Czytaj oryginał (ang.) |
| Theravance Biopharma, Inc. (TBPH) Q2 2024 Earnings Call Transcript |
Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainright David Risinger - Leerink Partners Ernie Rodriguez - TD Cowen Liisa Bayko - Evercore ISI Operator Ladies and gentlemen, good afternoon. |
seekingalpha.com |
2024-08-05 23:37:07 |
Czytaj oryginał (ang.) |
| Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates |
Theravance Biopharma (TBPH) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.13 per share a year ago. |
zacks.com |
2024-08-05 23:01:27 |
Czytaj oryginał (ang.) |
| Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update |
Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 2023 1 Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approved Now expecting last patient into the open label portion of CYPRESS in mid-2025, top line data anticipated approximately 6 months later Q2 2024 TRELEGY net sales of $1.065 billion, increasing the likelihood of achieving up to $50 million of milestones in 2024 Q2 2024 ending cash balance of $96.1 million DUBLIN , Aug. 5, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the second quarter of 2024. "YUPELRI net sales decreased 1% from the prior quarter, owing to near-term headwinds from an evolved channel mix and a lower realized net price," said Rick Winningham, Theravance Biopharma CEO. |
prnewswire.com |
2024-08-05 20:05:00 |
Czytaj oryginał (ang.) |
| Theravance Biopharma to Participate in an Upcoming Investor Conference |
DUBLIN , July 25, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 6 at 12:00 pm ET (9:00 am PT/5:00 pm IST). Members of Theravance Biopharma senior management will also be hosting one-on-one meetings at the conference. |
prnewswire.com |
2024-07-25 10:00:00 |
Czytaj oryginał (ang.) |